×

Kraig Biocraft Laboratories Enters Third Phase of Its Monster Silk(TM) Pilot Production Program Ahead of Schedule

LANSING, Mich., Feb. 28, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company" or "Kraig"), the leading developer of advanced spider silk based fiber technologies, announced today the launch of stage 3 of its pilot production program ("program").

The program is designed to run in three stages, each launching in turn when the data from the previous stage indicates that the program is reaching its benchmarks.

"The launch of stage three indicates stages 1 and 2 are exceeding our expectations with hatch rates exceeding 60%. At the current rates of the program's development, we should be able to announce that hatchlings from the first round have begun spinning Monster Silk™ within the next few days," said Company founder and CEO, Kim K. Thompson.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495 ir@KraigLabs.comSource:Kraig Biocraft Laboratories, Inc